Summary | |
---|---|
Symbol | IFNAR1 |
Name | interferon (alpha, beta and omega) receptor 1 |
Aliases | IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ...... |
Chromosomal Location | 21q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Isoform 1: Cell membrane Single-pass type I membrane protein Late endosome Lysosome Note=Interferon binding triggers internalization of the receptor from the cell membrane into endosomes and then into lysosomes. |
Domain |
PF09294 Interferon-alpha/beta receptor PF01108 Tissue factor |
Function |
Component of the receptor for type I interferons, including interferons alpha, IFNB1 and IFNW1 (PubMed:2153461, PubMed:7665574, PubMed:10049744, PubMed:14532120, PubMed:15337770, PubMed:21854986). Functions in general as heterodimer with IFNAR2 (PubMed:7665574, PubMed:10049744, PubMed:21854986). Type I interferon binding activates the JAK-STAT signaling cascade, and triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and the IFNR alpha- and beta-subunits themselves (PubMed:7665574, PubMed:21854986). Can form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway (By similarity). |
Biological Process |
GO:0001819 positive regulation of cytokine production GO:0001959 regulation of cytokine-mediated signaling pathway GO:0002237 response to molecule of bacterial origin GO:0007159 leukocyte cell-cell adhesion GO:0007259 JAK-STAT cascade GO:0009306 protein secretion GO:0009615 response to virus GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0032479 regulation of type I interferon production GO:0032481 positive regulation of type I interferon production GO:0032496 response to lipopolysaccharide GO:0032606 type I interferon production GO:0032608 interferon-beta production GO:0032609 interferon-gamma production GO:0032611 interleukin-1 beta production GO:0032612 interleukin-1 production GO:0032648 regulation of interferon-beta production GO:0032649 regulation of interferon-gamma production GO:0032651 regulation of interleukin-1 beta production GO:0032652 regulation of interleukin-1 production GO:0032728 positive regulation of interferon-beta production GO:0032729 positive regulation of interferon-gamma production GO:0032731 positive regulation of interleukin-1 beta production GO:0032732 positive regulation of interleukin-1 production GO:0034340 response to type I interferon GO:0035455 response to interferon-alpha GO:0035457 cellular response to interferon-alpha GO:0042089 cytokine biosynthetic process GO:0042107 cytokine metabolic process GO:0042110 T cell activation GO:0045088 regulation of innate immune response GO:0045351 type I interferon biosynthetic process GO:0050663 cytokine secretion GO:0050701 interleukin-1 secretion GO:0050702 interleukin-1 beta secretion GO:0050704 regulation of interleukin-1 secretion GO:0050706 regulation of interleukin-1 beta secretion GO:0050707 regulation of cytokine secretion GO:0050708 regulation of protein secretion GO:0050714 positive regulation of protein secretion GO:0050715 positive regulation of cytokine secretion GO:0050716 positive regulation of interleukin-1 secretion GO:0050718 positive regulation of interleukin-1 beta secretion GO:0050730 regulation of peptidyl-tyrosine phosphorylation GO:0051047 positive regulation of secretion GO:0051222 positive regulation of protein transport GO:0051607 defense response to virus GO:0060337 type I interferon signaling pathway GO:0060338 regulation of type I interferon-mediated signaling pathway GO:0060759 regulation of response to cytokine stimulus GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071357 cellular response to type I interferon GO:0071593 lymphocyte aggregation GO:0097696 STAT cascade GO:0098542 defense response to other organism GO:1903532 positive regulation of secretion by cell GO:1904951 positive regulation of establishment of protein localization |
Molecular Function |
GO:0004896 cytokine receptor activity GO:0004904 interferon receptor activity GO:0004905 type I interferon receptor activity GO:0019955 cytokine binding GO:0019961 interferon binding GO:0019962 type I interferon binding |
Cellular Component |
GO:0005770 late endosome |
KEGG |
hsa04060 Cytokine-cytokine receptor interaction hsa04151 PI3K-Akt signaling pathway hsa04380 Osteoclast differentiation hsa04620 Toll-like receptor signaling pathway hsa04621 NOD-like receptor signaling pathway hsa04630 Jak-STAT signaling pathway hsa04650 Natural killer cell mediated cytotoxicity |
Reactome |
R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-168256: Immune System R-HSA-913531: Interferon Signaling R-HSA-909733: Interferon alpha/beta signaling R-HSA-912694: Regulation of IFNA signaling |
Summary | |
---|---|
Symbol | IFNAR1 |
Name | interferon (alpha, beta and omega) receptor 1 |
Aliases | IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ...... |
Chromosomal Location | 21q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between IFNAR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between IFNAR1 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | IFNAR1 |
Name | interferon (alpha, beta and omega) receptor 1 |
Aliases | IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ...... |
Chromosomal Location | 21q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of IFNAR1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | IFNAR1 |
Name | interferon (alpha, beta and omega) receptor 1 |
Aliases | IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ...... |
Chromosomal Location | 21q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of IFNAR1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of IFNAR1 in various data sets.
|
Summary | |
---|---|
Symbol | IFNAR1 |
Name | interferon (alpha, beta and omega) receptor 1 |
Aliases | IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ...... |
Chromosomal Location | 21q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IFNAR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | IFNAR1 |
Name | interferon (alpha, beta and omega) receptor 1 |
Aliases | IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ...... |
Chromosomal Location | 21q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IFNAR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IFNAR1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | IFNAR1 |
Name | interferon (alpha, beta and omega) receptor 1 |
Aliases | IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ...... |
Chromosomal Location | 21q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IFNAR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | IFNAR1 |
Name | interferon (alpha, beta and omega) receptor 1 |
Aliases | IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ...... |
Chromosomal Location | 21q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of IFNAR1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | IFNAR1 |
Name | interferon (alpha, beta and omega) receptor 1 |
Aliases | IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ...... |
Chromosomal Location | 21q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between IFNAR1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | IFNAR1 |
Name | interferon (alpha, beta and omega) receptor 1 |
Aliases | IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ...... |
Chromosomal Location | 21q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting IFNAR1 collected from DrugBank database. |
Details on drugs targeting IFNAR1.
|